SS
AXSM icon

SBI Securities’s Axsome Therapeutics AXSM Stock Holding History

SBI Securities’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.23K Sell
25
-2
-7% -$345 ﹤0.01% 2104
2025
Q4 		$4.93K Buy
27
+6
+29% +$838 ﹤0.01% 2032
2025
Q3 		$2.55K Buy
21
+2
+11% +$225 ﹤0.01% 2328
2025
Q2 		$1.98K Sell
19
-10
-34% -$1.06K ﹤0.01% 2385
2025
Q1 		$3.38K Sell
29
-30
-51% -$3.42K ﹤0.01% 2062
2024
Q4 		$4.99K Buy
+59
New +$5.43K ﹤0.01% 1922

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities's AXSM Position: Q1 2026 in Review

SBI Securities reduced its Axsome Therapeutics (AXSM) stake by 7.4% in Q1 2026, selling an estimated $345 and leaving 25 shares worth $4.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

SBI Securities first reported a position in AXSM in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.99K in Q4 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • SBI Securities held 25 shares of Axsome Therapeutics worth $4.23K as of Q1 2026.
  • SBI Securities sold 2 Axsome Therapeutics shares in Q1 2026, an estimated $345.
  • Axsome Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2104 holding.
  • SBI Securities first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Axsome Therapeutics position peaked at $4.99K in Q4 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.